#SPro

4 months ago

#SPRO Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

www.stocktitan.net/news/SPRO/spero-therapeu...

0 0 0 0

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) Spero Therapeutics (NASDAQ: SPRO) and GSK reported positive Phase 3 PIVOT-PO results for oral tebipenem HBr in complicated urinary tract infections (cUTI), presented Oct 20, 2025 at IDWeek. The trial was stopped early for efficacy in May 2025 and met the primary endpoint of non-inferiority versus IV imipenem-cilastatin: overall success 58.5% (261/446) vs 60.2% (291/483); adjusted difference −1.3% (95% CI −7.5%, 4.8%). Clinical cure was 93.5% vs 95.2%; microbiological response ~60% in both arms. GSK plans to include data in a US filing in Q4 2025.

4 months ago

#SPRO PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

www.stocktitan.net/news/SPRO/pivot-po-phase...

0 0 0 0

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company

5 months ago

#SPRO Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

www.stocktitan.net/news/SPRO/spero-therapeu...

0 0 0 0

seraphy

@salvare.bsky.social

6 months ago

更に17時前
チャドシャッド180 Boneで
ストライパー2連発✨

ストライパーの追い込みポイントにて
リーリングジャークやって
ロングダートで通したらガッツン！！
いいバイトもらったぜ😁

稚鯉の時は
チビタレル、ガンタレル、ブルシューターで
経験則めっちゃあるからな

ただ、欲を言えば
ホントはグラヴィテーター220で
出したかったぜ〜〜〜💦

#SPRO
#KGB
#チャドシャッド180
#Chadshad180
#Bone

9 0 0 0

«Approval Processes in Switzerland Are Almost Embarrassingly Slow» Switzerland remains a hub for fintech thanks to its stability and innovation—yet according to Michael Barskyi, Head of S-PRO Switzerland and fintech expert, the financial center is at risk of losing its competitive edge. In this interview, he criticizes sluggish licensing procedures, a lack of strategic talent retention, and warns: «Switzerland can’t afford to act like a lame duck if it wants to maintain its leadership in blockchain.»

8 months ago

«Approval Processes in Switzerland Are Almost Embarrassingly Slow»: Switzerland remains a hub for fintech thanks to its stability and innovation—yet according to Michael Barskyi, Head of S-PRO Switzerland and fintech expert, the financial center is at risk of losing its… #MichaelBarskyi #spro

0 0 0 0

«Bewilligungsprozesse in der Schweiz gehen fast schon beschämend lange» Die Schweiz punktet bei Fintechs mit Innovationskraft und Stabilität – doch laut Michael Barskyi, dem Schweiz-Chef von S-Pro und Fintech-Experte, verspielt der Finanzplatz zunehmend seinen Vorsprung. Im Interview kritisiert er träge Bewilligungsprozesse, fehlende Talentstrategien und warnt: «Die Schweiz darf sich nicht wie eine lahme Ente verhalten, wenn sie ihre Führungsrolle im Blockchain-Bereich behalten will.»

8 months ago

«Bewilligungsprozesse in der Schweiz gehen fast schon beschämend lange»: Die Schweiz punktet bei Fintechs mit Innovationskraft und Stabilität – doch laut Michael Barskyi, dem Schweiz-Chef von S-Pro und Fintech-Experte, verspielt der Finanzplatz zunehmend seinen Vorsprung. Im… #MichaelBarskyi #spro

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed May 28th - #LVWR #VLRS #ETWO #IMNN #TRMD #SPRO #RIG #QUBT #OPEN #NVTS #MLGO #HYLN #HOLO #EVH #DAWN #BTCS #BORR #RXRX #ALLO #BTBT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading, Wed May 28th - #NFGC #VVPR #SPRO #PAYS #OPAL #MBAV #JUNS #IMCC #HOLO #GASS #EVAX #CKPT #BROG #ACRS #VCSA #SOL #RZB #LVWR #HYLN #ANVS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Dinero en USA 🇺🇸🪙

@dineroenusa.com

9 months ago

2/ EMPRESAS DESTACADAS

#SPRO: +244% tras detener estudio de fármaco para infecciones urinarias por éxito anticipado

#ANF: +6% tras superar expectativas en ventas de Q1 por demanda en jeans y vestidos

#NVDA: +3% por buenos ingresos

0 0 1 0

Market Wire News

@marketwirenews.com

9 months ago

News; ( NASDAQ: #SPRO ) Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

JUST IN: ( NASDAQ: #SPRO ) Spero Therapeutics and GSK Announce Early Completion of Phase 3 PIVOT-PO Trial for Oral Antibiotic Tebipenem HBr Based on Positive Efficacy Results

0 0 0 0

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee Spero Therapeutics (NASDAQ: SPRO) and GSK announced the early termination of their Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), due to meeting efficacy endpoints. The trial demonstrated non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients. The study's safety profile aligned with previous findings, with diarrhea and headache as primary adverse events. If approved, tebipenem HBr would become the first oral carbapenem antibiotic for US cUTI patients. With an estimated 2.9 million cUTI cases annually in the US, contributing to over $6 billion in yearly healthcare costs, GSK plans to submit FDA filing in 2H 2025.

9 months ago

#SPRO Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

www.stocktitan.net/news/SPRO/spero-therapeu...

0 0 0 0

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update Spero Therapeutics (NASDAQ: SPRO) reported Q1 2025 financial results and provided key updates. The company posted a net loss of $13.9 million ($0.25 per share) compared to $12.7 million loss in Q1 2024. Total revenue decreased to $5.9 million from $9.3 million year-over-year. The company's lead candidate, tebipenem HBr, an oral carbapenem antibiotic for complicated urinary tract infections, is progressing with a pre-specified interim analysis of Phase 3 PIVOT-PO trial expected in Q2 2025. The company appointed Esther Rajavelu as President and CEO effective May 2, 2025. Spero ended Q1 with $48.9 million in cash, which, combined with $23.75M in upcoming GSK milestone payments, is expected to fund operations into Q2 2026. The SPR720 program for NTM-PD was suspended in Q4 2024 after failing to meet primary endpoints in Phase 2a study.

10 months ago

#SPRO Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

www.stocktitan.net/news/SPRO/spero-therapeu...

0 0 0 0

cctv Geek

@areavisum12.bsky.social

10 months ago

de-beste-Beveiligingscamera , bewakingscamera-systemen . Areavisum biedt hoogwaardige beveiligingssystemen voor bedrijven & particulieren. Kies voor veiligheid, zekerheid en gemak met onze gecertificeerde oplossingen.

We kunnen even vooruit , een gedeelte is er al .

#bewakingscamera #spro #installatie #alarm #drachten #kootstertille #leeuwarden #franeker #areavisum #beveiliging #dahua #tiandy #hikvision #comelit #areavisum
www.instagram.com/reel/DI4FeQ3...

0 0 0 0

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update Spero Therapeutics (SPRO) announced its Q4 and full-year 2024 financial results, reporting a net loss of $(20.9) million for Q4 and $(68.6) million for the full year. Total revenue decreased to $15.0 million in Q4 2024 from $73.5 million in Q4 2023.Key pipeline updates include:Pre-specified interim analysis of Phase 3 PIVOT-PO trial for tebipenem HBr in complicated urinary tract infection expected in Q2 2025SPR720 program for NTM-PD under review following missed primary endpoint in Phase 2 studySPR206 program discontinued after pipeline reprioritization in Q1 2025The company's cash position stands at $52.9 million, with runway extending into Q2 2026, supported by GSK milestone payments. Leadership changes include Esther Rajavelu's appointment as Interim CEO following a SEC Wells Notice related to certain public disclosures from March-May 2022.

11 months ago

#SPRO Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

www.stocktitan.net/news/SPRO/spero-therapeu...

0 0 0 0

Internationaler IT-Experte: «Schweiz fehlt Innovation wie Revolut» Igor Izraylevych will mit seinem Unternehmen S-Pro den Finanzplatz in Sachen künstlicher Intelligenz voranbringen. Die Voraussetzungen hierzulande seien sehr gut, sagt er. Doch in Sachen Innovationen fehle der Schweiz die Krönung.

11 months ago

Internationaler IT-Experte: «Schweiz fehlt Innovation wie Revolut»: Igor Izraylevych will mit seinem Unternehmen S-Pro den Finanzplatz in Sachen künstlicher Intelligenz voranbringen. Die Voraussetzungen hierzulande seien sehr gut, sagt er. Doch in Sachen Innovationen fehle der… #spro #software

0 0 0 0

Internationaler IT-Experte: «Schweiz fehlt Innovation wie Revolut» Igor Izraylevych will mit seinem Unternehmen S-Pro den Finanzplatz in Sachen künstlicher Intelligenz voranbringen. Die Voraussetzungen hierzulande seien sehr gut, sagt er. Doch in Sachen Innovationen fehle der Schweiz die Krönung.

11 months ago

Internationaler IT-Experte: «Schweiz fehlt Innovation wie Revolut»: Igor Izraylevych will mit seinem Unternehmen S-Pro den Finanzplatz in Sachen künstlicher Intelligenz voranbringen. Die Voraussetzungen hierzulande seien sehr gut, sagt er. Doch in Sachen Innovationen fehle der… #spro #software

0 0 0 0

Switzerland Needs a Fintech Game Changer Like Revolut, says international IT CEO Igor Izraylevych sees immense potential in Switzerland’s financial sector but believes a true innovation like Revolut is missing. His company S-Pro aims to push AI advancements to help bridge that gap.

11 months ago

Switzerland Needs a Fintech Game Changer Like Revolut, says international IT CEO: Igor Izraylevych sees immense potential in Switzerland’s financial sector but believes a true innovation like Revolut is missing. His company S-Pro aims to push AI advancements to help bridge that gap. #spro #software

1 0 0 0

cctv Geek

@areavisum12.bsky.social

1 year ago

We verkopen veiligheid Welkom bij onze website, dé specialist in installatie services en beveiligingsoplossingen. Ontdek ons uitgebreide assortiment aan CCTV-systemen, alarmsystemen en bewakingscamera's van topmerken zoals ...

#Hikvision het hele assortiment op aanvraag leverbaar en evt geïnstalleerd.

Naast #dahua #comelit #tiandy #SPRO

CCTVNederland.nl

#intercom #beveiligingscamera #camerabewaking #areavisum #beveiliging #cctvnederland

Bel voor een afspraak of advies 058-2893820
www.instagram.com/reel/DF9_WfF...

1 0 0 0

Tom Staniford

@tomstaniford.bsky.social

1 year ago

I love to watch the crèma rise.
#coffee #espresso #spro

13 0 0 1

サードニュース@相互フォロー100%

@new3rd.bsky.social

1 year ago

アーサー・ディ・リトルが新たな経営戦略フレームワーク「SPRO」と「VSPRO」を商標登録 アーサー・ディ・リトル・ジャパンが「SPRO」とその進化版「VSPRO」を商標登録しました。新たな経営戦略の手法を紹介します。

アーサー・ディ・リトルが新たな経営戦略フレームワーク「SPRO」と「VSPRO」を商標登録 #東京都 #港区 #アーサー・ディ・リトル #SPRO #VSPRO

アーサー・ディ・リトル・ジャパンが「SPRO」とその進化版「VSPRO」を商標登録しました。新たな経営戦略の手法を紹介します。

0 0 0 0